Focal Segmental
Glomerulosclerosis Market – Drivers
As there is no drug approved for
the treatment of FSGS yet. Thus, limited treatment therapy and government
funding for research on rare diseases are expected to drive growth of the Focal
Segmental Glomerulosclerosis Market. For instance, in 2015, the U.S. Food
and Drug Administration (FDA) and European Commission both granted Sparsentan,
as orphan drug designation for the treatment of FSGS. This Sparsentan is a
novel drug candidate with dual mechanism of action combines angiotensin
receptor blockade with endothelin receptor blockade and is currently being
evaluated in a Phase III trial, which expected to complete in December 2022.
Increasing research and
development for FSGS drugs by various manufacturers is also fueling growth of
the FSGS market. For instance, Pfizer Inc., is undergoing clinical trial for
the evaluation of its drug, PF-06730512 in adults with primary focal segmental
glomerulosclerosis. This drug is currently in Phase II study and is expected to
complete in June 2021.
Focal Segmental
Glomerulosclerosis (FSGS) is a rare kidney disease affecting the kidney's
filtering system (glomeruli) and resulting in serious scarring and end stage
renal disease. For instance, according to the article in Clinical Journal of
American Society of Nephrology, 2017, FSGS incidence rates are often higher in
men, an estimated 1.5-fold higher as compared to women. FSGS is characterized
by symptoms such as edema, proteinuria, weight gain, increased cholesterol, and
proteins in blood.
* The sample copy includes:
Report Summary, Table of Contents, Segmentation, Competitive Landscape, Report
Structure, Methodology.
Request a sample copy
of this report: https://www.coherentmarketinsights.com/insight/request-sample/2224
Moreover, government investments
into the rare disease treatment is expected to drive the growth of market. For
instance, according to an annual data report from the U.S. Renal Data System
2017, Medicare invested around US$ 34 billion for people on dialysis with
chronic kidney disease.
Focal Segmental Glomerulosclerosis
Market – Restraint
Lack of awareness among
population regarding this disease and high cost of dialysis therapy may
restrict growth of this market to some extent. For instance, according to an
article published in University of Michigan 2017, awareness among patients with
FSGS is considerably low when the patients are in primary stage of FSGS, which
is hampering growth of the FSGS market.
Focal Segmental Glomerulosclerosis
Market – Regional Analysis
On the basis of region, the
global focal segmental glomerulosclerosis market is segmented into North
America, Latin America, Europe, Asia Pacific, Middle East, and Africa.
North America is expected to
dominate the FSGS market due to high prevalence of FSGS along with chronic
kidney diseases. For instance, According to an annual data report by the U.S.
Renal Data System 2017, the overall burden of kidney disease, kidney failure
with dialysis, and kidney transplantation is highest in U.S., thus driving the
growth of the focal segmental glomerulosclerosis market.
Browse Research
Report: https://www.coherentmarketinsights.com/ongoing-insight/focal-segmental-glomerulosclerosis-market-2224
Asia Pacific region is expected
to witness significant growth in market due to collaboration agreements and
partnerships among various players. For instance, Oraxion Therapeutics, Inc., a
subsidiary of Indian company Aten Porus, is undergoing preclinical and efficacy
study of the drug, ORX-301, which can be used in the treatment of FSGS. In
February 2018, Oraxion Therapeutics, Inc., entered into an Option Agreement
with the U.S-based Biopharmaceutical Company and under this agreement, U.S. based
company gets exclusive rights for further clinical studies and license of this
drug in the U.S.
The key players operating in the
focal segmental glomerulosclerosis (FSGS) market include GlaxoSmithKline plc.,
Novartis AG, Variant Pharmaceuticals, Inc., ChemoCentryx, Inc., Retrophin,
Inc., AbbVie, Inc., Pfizer, Inc., AstraZeneca plc., Sanofi S.A, and Teva Pharmaceutical Industries Ltd.
Buy-Now this research
report: https://www.coherentmarketinsights.com/insight/buy-now/2224
About
Coherent Market Insights:
Coherent
Market Insights is a prominent market research and consulting firm offering
action-ready syndicated research reports, custom market analysis, consulting
services, and competitive analysis through various recommendations related to
emerging market trends, technologies, and potential absolute dollar
opportunity.
Contact
Us:
mailto:sales@coherentmarketinsights.com
U.S.
Office:
Name: Mr. Shah
Coherent
Market Insights 1001 4th Ave,
# 3200
Seattle, WA 98154, U.S.
US : +1-206-701-6702
UK : +44-020-8133-4027
JAPAN : +050-5539-1737
No comments:
Post a Comment